Osimertinib

Osimertinib, sold under the brand name Tagrisso,^[1] is a medication used to treat non-small-cell lung carcinomas with specific mutations.[5][6] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

ReferencesReferences

↑ "Proposed INN: List 113" (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Michal Harel

[a4-1] "Proposed INN: List 113" (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015

[1]